Cocrystal Pharma (COCP) Other financing activities (2011 - 2020)

Cocrystal Pharma (COCP) posted Other financing activities of -$11000.0 for Q3 2020, down 375.0% sequentially from $4000.0 in Q2 2020.

Cocrystal Pharma (COCP) Other financing activities (2011 - 2020) Analysis & Trends

Cocrystal Pharma has reported Other financing activities for 6 years, with the latest figure at -$11000.0 in Q3 2020.

Quarterly Other financing activities changed N/A year-over-year to -$11000.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $4000.0 (up 102.07% YoY) and the FY2019 annual result came in at -$10000.0, down 11.11% from the prior year.
Other financing activities fell to -$11000.0 in Q3 2020 per COCP's latest filing, from $4000.0 in the prior quarter.
Over five years, Other financing activities peaked at $184000.0 in Q1 2018 and troughed at -$194000.0 in Q4 2018.
A 3-year average of -$285.71 and a median of $3000.0 in 2016 frame the typical range for Other financing activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cocrystal Pharma	15.65 Mn	13.33 Mn	-

Download Data